New directions in the treatment of Gaucher disease

Trends in Pharmacological Sciences

Volumn 25, Issue 3, 2004, Pages 147-151

  Futerman, Anthony H ^a   Sussman, Joel L ^a   Horowitz, Mia ^b   Silman, Israel ^a   Zimran, Ari ^c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; IMIGLUCERASE; MIGLUSTAT;

CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DETERMINATION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; ENZYME REPLACEMENT; GAUCHER DISEASE; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 1342306744     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.01.004     Document Type: Article

References (27)

1. Zimran A. Gaucher's Disease. 1997;Balliere Tindall.
2. Beutler E., Grabowski G.A. Gaucher disease. Scriver C.R., et al. The Metabolic and Molecular Bases of Inherited Disease. Vol. II:2001;3635-3668 McGraw-Hill.
3. Horowitz M., Zimran A. Mutations causing gaucher disease. Hum. Mutat. 3:1994;1-11.
4. Zhao H., Grabowski G.A. Gaucher disease: perspectives on a prototype lysosomal disease. Cell. Mol. Life Sci. 59:2002;694-707.
5. Weinreb N.J., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am. J. Med. 113:2002;112-119.
6. Lachmann R.H. Miglustat. Oxford GlycoSciences/Actelion. Curr. Opin. Investig. Drugs. 4:2003;472-479.
7. Grabowski G.A., Hopkin R.J. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu. Rev. Genomics Hum. Genet. 4:2003;403-436.
8. Cox T., et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 355:2000;1481-1485.
9. Zimran A., Elstein D. Gaucher disease and the clinical experience with substrate reduction therapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358:2003;961-966.
10. Heitner R., et al. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol. Dis. 28:2002;127-133.
11. Cox T.M., et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type 1 (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 26:2003;513-526.
12. Platt F.M., et al. Prevention of lysosomal storage disease in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 276:1997;428-431.
13. Kolter T., et al. Combinatorial ganglioside biosynthesis. J. Biol. Chem. 277:2002;25859-25862.
14. Buccoliero R., et al. The role of sphingolipids in neuronal development: lessons from models of sphingolipid storage diseases. Neurochem. Res. 27:2002;565-574.
15. Fan J.Q. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol. Sci. 24:2003;355-360.
16. Sawkar A.R., et al. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 99:2002;15428-15433.
17. Dvir H., et al. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 4:2003;704-709.
18. Grace M.E., et al. Analysis of human acid β-glucosidase by site-directed mutagenesis and heterologous expression. J. Biol. Chem. 269:1994;2283-2291.
19. Mistry P.K., et al. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet. 348:1996;1555-1559.
20. Cox T.M. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J. Inherit. Metab. Dis. 24:(Suppl. 2):2001;106-121.
21. Moran M.T., et al. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood. 96:2000;1969-1978.
22. Boot R.G., et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 103:2004;33-39.
23. Bodennec J., et al. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide. FASEB J. 16:2002;1814-1816.
24. Korkotian E., et al. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem. 274:1999;21673-21678.
25. Lloyd-Evans E., et al. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J. Biol. Chem. 278:2003;23594-23599.
26. Smith W.L., Merrill A.H. Jr. Sphingolipid metabolism and signaling minireview series. J. Biol. Chem. 277:2002;25841-25842.
27. Beutler E. Economic malpractice in the treatment of Gaucher's disease. Am. J. Med. 97:1994;1-2.